Skip to main content

Better Choice Company Appoints Renowned Expert in Rare and Undiagnosed Diseases, Dr. Paldeep S. Atwal, as its United States Special Healthcare Advisor

Written by Customer Service on . Posted in Public Companies.

TAMPA, Fla., March 04, 2025 (GLOBE NEWSWIRE) — Better Choice Company, Inc. (NYSE American: BTTR) (“Better Choice” or the “Company”), a pet health and wellness company, today announced the appointment of Dr. Paldeep S. Atwal as its United States Special Healthcare Advisor.

Renowned for his expertise in rare and undiagnosed diseases, Dr. Atwal has dedicated his career to advancing the field of genomic medicine through cutting-edge diagnostics, research, and patient care. Dr. Atwal is a board-certified clinical and medical biochemical geneticist and the founder of Atwal Clinic for Genomic & Personalized Medicine, a premier private genetics clinic in Palm Beach, FL. Previously, he served as Medical Director of Genetic Services at Everly Health Solutions (formerly PWNHealth), a leading virtual healthcare company, and as Medical Director for the Individualized Medicine Clinic at Mayo Clinic in Florida, where he played a pivotal role in advancing precision medicine initiatives.

“As we near the closing of our acquisition of SRx Health, it is critical we continue to build our team with healthcare professionals and experts such as Dr. Atwal,” said Michael Young, Chairman of Better Choice. “Dr. Atwal’s appointment will be key in accelerating the our growth, particularly in new offerings, strategic healthcare partnerships, and aligning with the evolving wellness and preventative health landscape. Dr. Atwal’s pioneering work in genomic medicine, combined with his vast expertise in rare diseases and personalized care, will be invaluable as we continue to innovate and expand our health and wellness offerings. His strategic vision will be instrumental in shaping our future initiatives and ensuring we lead the way in delivering impactful health solutions that truly improve lives.”

As a recognized leader in genomic medicine, Dr. Atwal is committed to advancing personalized, science-driven care, with his pioneering contributions earning numerous prestigious awards, including the ACMG Foundation/Genzyme Fellowship, and the Neurobiology of Disease in Children Young Investigator Award. Dr. Atwal earned his medical degree from the University of Glasgow and trained in internal medicine at Glasgow Royal Infirmary with the Royal College of Physicians. He also pursued a genetics fellowship at Stanford University and a sub-specialty biochemical genetics fellowship at Baylor College of Medicine, where he contributed to the development of a clinical metabolomic profiling test.

About Better Choice Company Inc.
Better Choice Company Inc. is a rapidly growing pet health and wellness company committed to leading the industry shift toward pet products and services that help dogs and cats live healthier, happier, and longer lives. We take an alternative, nutrition-based approach to pet health relative to conventional dog and cat food offerings and position our portfolio of brands to benefit from the mainstream trends of growing pet humanization and consumer focus on health and wellness. We have a demonstrated, multi-decade track record of success selling trusted pet health and wellness products and leverage our established digital footprint to provide pet parents with the knowledge to make informed decisions about their pet’s health. We sell the majority of our dog food, cat food and treats under the Halo brand, which is focused, respectively, on providing sustainably sourced kibble and canned food derived from real whole meat, and minimally processed raw-diet dog food and treats. For more information, please visit https://www.betterchoicecompany.com.

Forward Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. The words “believe,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. The Company has based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Some or all of the results anticipated by these forward-looking statements may not be achieved. Further information on the Company’s risk factors is contained in our filings with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.

Company Contact:
Better Choice Company, Inc.
Kent Cunningham, CEO

Investor Contact:
KCSA Strategic Communications
Valter Pinto, Managing Director
T: 212-896-1254
Valter@KCSA.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.